Science News
from research organizations

Risk of low blood sugar differs among similar diabetes drugs

Date:
July 19, 2016
Source:
Wiley
Summary:
Adding sulphonylureas (SUs) to metformin remains a commonly used strategy for treating type 2 diabetes, but individual SUs differ and may confer different risks of abnormally low blood sugar, or hypoglycemia. SUs -- which include newer generation agents such as gliclazide, glipizide, glimepiride, and glibenclamide -- stimulate the production of insulin in the pancreas and increase the effectiveness of insulin in the body.
Share:
FULL STORY

Adding sulphonylureas (SUs) to metformin remains a commonly used strategy for treating type 2 diabetes, but individual SUs differ and may confer different risks of abnormally low blood sugar, or hypoglycemia. SUs -- which include newer generation agents such as gliclazide, glipizide, glimepiride, and glibenclamide -- stimulate the production of insulin in the pancreas and increase the effectiveness of insulin in the body.

A new systematic review of randomized clinical trials lasting 12 to 52 weeks found that when added to metformin, gliclazide confers the lowest risk of hypoglycemia compared with glipizide, glimepiride, and glibenclamide.

"Risk of hypoglycemia with the SU agents makes the newer and more expensive antidiabetics preferable when metformin monotherapy fails. However, our data indicate that the risk of hypoglycemia differs between the SU agents," said Dr. Stig Ejdrup Andersen, co-author of the British Journal of Clinical Pharmacology analysis. "Thus, prescribing an SU with low risk of hypoglycemia might still be a rational and affordable alternative to many patients with type 2 diabetes."


Story Source:

Materials provided by Wiley. Note: Content may be edited for style and length.


Journal Reference:

  1. S. E. Andersen, M. Christensen. Hypoglycaemia when Adding Sulphonylurea to Metformin: A Systematic Review and Network Meta-analysis. British Journal of Clinical Pharmacology, 2016; DOI: 10.1111/bcp.13059

Cite This Page:

Wiley. "Risk of low blood sugar differs among similar diabetes drugs." ScienceDaily. ScienceDaily, 19 July 2016. <www.sciencedaily.com/releases/2016/07/160719105800.htm>.
Wiley. (2016, July 19). Risk of low blood sugar differs among similar diabetes drugs. ScienceDaily. Retrieved May 29, 2017 from www.sciencedaily.com/releases/2016/07/160719105800.htm
Wiley. "Risk of low blood sugar differs among similar diabetes drugs." ScienceDaily. www.sciencedaily.com/releases/2016/07/160719105800.htm (accessed May 29, 2017).

RELATED STORIES